Skip to main content

What the FDA labels say about taking them together

Propafenone and tizanidine

Tizanidine's FDA label of January 2, 2026 names propafenone in its drug interactions section; the propafenone label PlainMeds reads does not name tizanidine. The tizanidine label: “Adverse reactions such as hypotension, bradycardia, or excessive drowsiness can occur when Zanaflex is taken with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than ciprofloxacin (which is …”

Check it at the source: the propafenone FDA label on DailyMed (effective September 1, 2025, Strides Pharma Science Limited); the tizanidine FDA label on DailyMed (effective January 2, 2026, Legacy Pharma USA, Inc.).

What does the propafenone label say about tizanidine?

Propafenone's label (effective September 1, 2025) does not name tizanidine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (PROPAFENONE HYDROCHLORIDE), Strides Pharma Science Limited, effective September 1, 2025 (SPL set c65253ab-937f-4982-b841-69c2b9f9ccdb), via openFDA; the full label on DailyMed

What does the tizanidine label say about propafenone?

Tizanidine label, drug interactions

Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Zanaflex label (Covis Pharma US, Inc, May 5, 2025), drug interactions

Inhibitors other than Fluvoxamine and Ciprofloxacin Because of potential drug interactions, concomitant use of Zanaflex with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than strong CYP1A2 inhibitors (which are contraindicated), antiarrhythmics (amiodarone, mexiletine, propafenone, and verapamil), cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Zanaflex label (Covis Pharma US, Inc, May 5, 2025), warnings and precautions

Adverse reactions such as hypotension, bradycardia, or excessive drowsiness can occur when Zanaflex is taken with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than ciprofloxacin (which is contraindicated), antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine).

Ontralfy label (Rosemont Pharmaceuticals, LLC, October 25, 2025), drug interactions

Concomitant use of Ontralfy with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Source: FDA drug label (Zanaflex, NDA020397), Covis Pharma US, Inc, effective May 5, 2025 (SPL set 043d9e51-bfa2-4add-9058-5ece332f7e99), via openFDA

Source: FDA drug label (Ontralfy, NDA216190), Rosemont Pharmaceuticals, LLC, effective October 25, 2025 (SPL set 7b88c338-c0b7-4c08-bef6-a4ffc2f25df7), via openFDA

Source: FDA drug label (Zanaflex), Legacy Pharma USA, Inc., effective January 2, 2026 (SPL set 60c27d35-7349-4fc6-86ad-70fffdbe3e08), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Propafenone generic labelers
49Tizanidine generic labelers
PropafenoneTizanidine
Labeled forAtrial fibrillationMuscle spasms and spasticity
Boxed warningYesNo
Pharmacy cost (NADAC)$0.115 per tablet 150 mg tablet$0.0331 per tablet 4 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?